Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)
Claudio Vernieri(Fondazione IRCCS Istituto Nazionale dei Tumori), Filippo de Braud(University of Milan), Massimo Milione(Fondazione IRCCS Istituto Nazionale dei Tumori), Pietro Indelicato(Fondazione IRCCS Istituto Nazionale dei Tumori), Marco Foiani(Istituto di Genetica Molecolare), Sara Pusceddu(Fondazione IRCCS Istituto Nazionale dei Tumori), Stefano Casola(IFOM), Serenella M. Pupa(Tumori Foundation), Lorenzo Castagnoli(Fondazione IRCCS Istituto Nazionale dei Tumori), Giovanni Centonze(Fondazione IRCCS Istituto Nazionale dei Tumori), Vincenzo Mazzaferro(Fondazione IRCCS Istituto Nazionale dei Tumori), Giancarlo Pruneri(University of Milan), Giovanni Fucà(AstraZeneca (Spain)), Elisa Ferrari(IFOM), Arta Ajazi(IFOM)
Cited by 65
Related Papers
Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with Cirrhosis
|New England Journal of Medicine|1996|7.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Regulation of the Germinal Center Response by MicroRNA-155
|Science|2007|1.5k
Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
|New England Journal of Medicine|2008|1.3k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835